Skip to main content Skip to navigation

Life Sciences News

See our Latest Journal Publications 

Show all news items

Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections.

Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage. The candidate, which will be developed by Poolbeg as POLB 002, was developed at the University of Warwick and derived from twenty years of research with world class virologists, Professor Andrew Easton and Professor Nigel Dimmock.

Press release (17 January 2022)

Mon 17 Jan 2022, 12:09 | Tags: Biomedical Science Press Release Faculty of Science